Pretomanid, aslo known as PA-824, a bioreductive drug. PA-824 has potent in vitro activity against Mycobacterium tuberculosis. PA-824 was tested in vitro against a broad panel of multidrug-resistant clinical isolates and was found to be highly active against all isolates (MIC<1 microg/ml). PA-824 showed significant activity at 2, 10, and 50 microg/ml, similar to that of metronidazole, in a dose-dependent manner. PA-824's good activity in in vivo models, as well as its activity against multidrug-resistant M. tuberculosis and against M. tuberculosis isolates in a potentially latent state, makes PA-824 an attractive drug candidate for the therapy of tuberculosis.
Properties:
Density: 1.58g/cm3
Boiling Point: 462.3ºC at 760 mmHg
Flash Point: 233.4ºC
Refractive Index: 1.588
Vapor Pressure: 1E-08mmHg at 25°C
Bacterial inhibitor Related Products:
Pyrazinamide; Sulfanilamide; Walrycin B; Daptomycin; Tigecycline; Rifabutin; Biapenem; Teicoplanin; Cefditoren Pivoxil; Cefdinir; Azithromycin; Trimethoprim; Vancomycin HCl; Amoxicillin; Dalbavancin; Cefoxitin acid; Ceftibuten dihydrate; Besifloxacin; Solithromycin; Cefditoren; Dalbavancin HCl; Cefoxitin Sodium; Besifloxacin Hydrochloride; Pleuromutilin